# CJC-1295 (no DAC) dosage guide

> Review CJC-1295 (no DAC) dosage information by administration route, with source-linked dose and schedule details.

Canonical: https://pepflow.app/peptides/cjc-1295-no-dac/dosage/

Review short-acting CJC-1295 without DAC, including injection frequency, gradual progressions and timing around daily routines. Calculate volume and syringe units using your own vial inputs.

[Full CJC-1295 (no DAC) library reference](<https://pepflow.app/peptides/cjc-1295-no-dac/>)

## CJC-1295 (no DAC) dosage chart

This summary table compares available dose amounts and schedules by administration route.

| Route | Dose | Frequency & duration |
| --- | --- | --- |
| Injectable | 100–200 mcg | 1–3x daily · 8–12 wk |

## CJC-1295 (no DAC) dosage by administration route

### CJC-1295 (no DAC) injectable dosage

Reported-use amounts for CJC-1295 (no DAC) are 100–200 mcg per administration, 1–3x daily, for 8–12 wk. A gradual subcutaneous progression starts at 100 mcg in weeks 1–2, increases to 150 mcg in weeks 3–4, then reaches 200–300 mcg in weeks 5–12. Schedules include once-daily administration and a separate two-to-three-times-weekly pattern.[\[12\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-12>) [\[13\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-13>)

The no-DAC form is a short-acting Modified GRF 1-29 analogue. Its pulse-oriented GH signaling differs from the prolonged action of DAC-containing CJC-1295.[\[1\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-1>) [\[2\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-2>) [\[3\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-3>) [\[4\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-4>) [\[5\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-5>) [\[12\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-12>)

### Frequency and timing

Common injection timing is morning, after a workout or before bed.[\[2\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-2>) [\[12\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-12>)

### Cycle length and breaks

Injectable: 8–12 wk. A standard break interval between courses is not established.[\[12\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-12>)

## CJC-1295 (no DAC) dosage calculator

Convert your chosen CJC-1295 (no DAC) amount into volume and U-100 syringe units. Adjust the inputs to match your vial and preparation.

For preparation terms and concentration basics, see the [reconstitution guidelines](<https://pepflow.app/peptide-reconstitution-guidelines/>). Follow the arithmetic in the [concentration calculation walkthrough](<https://pepflow.app/blog/how-to-calculate-final-concentration/>).

## CJC-1295 (no DAC) safety and side effects

### Approval and product quality

CJC-1295 (no DAC) is not an FDA-approved drug.[\[10\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-10>)

### Side effects and long-term safety

Injection-site reactions, flushing, headache, dizziness, blood-pressure symptoms and faster heart rate are relevant adverse effects. Long-term endocrine safety, glucose effects, interactions and product purity remain uncertain.[\[6\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-6>) [\[7\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-7>) [\[5\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-5>) [\[11\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-11>)

### Route-specific dosing limits

GH/IGF-1 effects and anti-doping restrictions require attention. Medical review is especially important for endocrine disease, glucose dysregulation, cancer or growth-factor-sensitive histories, pregnancy, breastfeeding, pediatric use, and competitive sport. Reported-use injectable schedules and additional protocol patterns are not established human treatment regimens or approved product instructions.[\[10\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-10>) [\[7\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-7>) [\[13\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-13>) [\[12\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-12>)

## Stacks that include CJC-1295 (no DAC)

Open a stack dosage guide for its component amounts, schedules and supporting information.

[**GH Stack** GH Stack pairs CJC-1295 no DAC with Ipamorelin. It combines a short-acting GHRH-side analog with Ipamorelin's ghrelin/GHS-receptor signal to organize discrete GH-release windows. CJC-1295 (no DAC) Ipamorelin](<https://pepflow.app/stacks/cjc-1295-no-dac-ipamorelin/dosage/>)

For a blend calculation, each component's amount and the final volume must be known. A total blend weight alone cannot tell you the dose of each component.

## Common CJC-1295 (no DAC) dosage questions

### What is the CJC-1295 no DAC dose?

Common Modified GRF 1-29 protocols usually use 100-200 mcg per dose, 1-3 times daily, with morning, post-workout, or before-bed timing.

### Is there a standard human dose of CJC-1295 (no DAC)?

A transferable human dose for CJC-1295 (no DAC) has not been established. A product strength or reminder amount does not establish a treatment regimen.[\[12\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-12>)

### Does CJC-1295 (no DAC) have a standard cycle or break interval?

Injectable: 8–12 wk. A standard break interval between courses is not established.[\[12\]](<https://pepflow.app/peptides/cjc-1295-no-dac/dosage/#source-12>)

## Sources

- [\[1\] **Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.** PubMed / Journal of Clinical Endocrinology and Metabolism, 1992. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/1379256/>)
- [\[2\] **Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.** PubMed / Metabolism, 1997. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/9005976/>)
- [\[3\] **Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men.** PubMed / Journal of Clinical Endocrinology and Metabolism, 1994. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/7962295/>)
- [\[4\] **Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.** PubMed / Endocrinology, 2005. animal.](<https://pubmed.ncbi.nlm.nih.gov/15817669/>)
- [\[5\] **FDA Evaluation of CJC-1295 Related Bulk Drug Substances for the December 4, 2024 Pharmacy Compounding Advisory Committee Meeting** U.S. Food and Drug Administration, 2024. regulatory.](<https://www.fda.gov/media/183819/download>)
- [\[6\] **Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men.** PubMed / Peptides, 1985. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/2866496/>)
- [\[7\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration, 2026-04-22. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[8\] **Ipamorelin, the first selective growth hormone secretagogue.** European journal of endocrinology, 1998 Nov. review.](<https://pubmed.ncbi.nlm.nih.gov/9849822/>)
- [\[9\] **Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.** Pharmaceutical research, 1999 Sep. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/10496658/>)
- [\[10\] **Search Drugs@FDA for CJC-1295 no-DAC and Modified GRF 1-29** openFDA / U.S. Food and Drug Administration. database query.](<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>)
- [\[11\] **Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.** PubMed / Sports Medicine, 2026. review.](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)
- [\[12\] **PepFlow peptide cheat sheet — reported-use and product-orientation reference (not clinical research)** PepFlow. reference catalog.](<https://pepflow.app/peptide-cheat-sheet/>)
- [\[13\] **CJC-1295 No DAC — Everything Peptide reported protocol (educational reference, not clinical evidence)** Everything Peptide. reference catalog.](<https://everythingpeptide.com/protocol-cjc-1295-no-dac.html>)

[Full CJC-1295 (no DAC) library reference →](<https://pepflow.app/peptides/cjc-1295-no-dac/>)

## Related

- [CJC-1295 (no DAC) Peptide](<https://pepflow.app/peptides/cjc-1295-no-dac/>)
- [Peptide reconstitution guidelines](<https://pepflow.app/peptide-reconstitution-guidelines/>)
- [How to Calculate Final Concentration: A Practical Guide](<https://pepflow.app/blog/how-to-calculate-final-concentration/>)
- [GH Stack dosage guide](<https://pepflow.app/stacks/cjc-1295-no-dac-ipamorelin/dosage/>)
